Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Jäger T, Neureiter D, Fallaha M, Schredl P, Kiesslich T, Urbas R, Klieser E, Holzinger J, Sedlmayer F, Emmanuel K, Dinnewitzer A.

Strahlenther Onkol. 2018 Aug 1. doi: 10.1007/s00066-018-1340-0. [Epub ahead of print]

PMID:
30069738
2.

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Greil R, Pleyer L, Jansko B, Feierabend C, Rettenbacher L, Stiefel O, Rass C, Morre P, Neureiter D, Greil-Ressler S.

Oncotarget. 2018 Apr 17;9(29):20928-20940. doi: 10.18632/oncotarget.25037. eCollection 2018 Apr 17.

3.

Alterations of Oxidative Phosphorylation Complexes in Papillary Thyroid Carcinoma.

Zimmermann FA, Neureiter D, Sperl W, Mayr JA, Kofler B.

Cells. 2018 May 9;7(5). pii: E40. doi: 10.3390/cells7050040.

4.

Endoscopic submucosal dissection (ESD) for anal high-grade intraepithelial neoplasia: a case report.

Wagner A, Neureiter D, Holzinger J, Kiesslich T, Klieser E, Berr F.

Z Gastroenterol. 2018 May;56(5):495-498. doi: 10.1055/a-0578-9059. Epub 2018 May 7.

PMID:
29734448
5.

In-situ analysis of mast cells and dendritic cells in coronary atherosclerosis in chronic kidney disease (CKD).

Wachter DL, Neureiter D, Câmpean V, Hilgers KF, Büttner-Herold M, Daniel C, Benz K, Amann K.

Histol Histopathol. 2018 Aug;33(8):871-886. doi: 10.14670/HH-11-988. Epub 2018 Apr 4.

PMID:
29616745
6.

Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D).

Aigner E, Feldman A, Neureiter D, Datz C, Ratziu V, Paulweber B.

Am J Gastroenterol. 2018 Mar;113(3):443-445. doi: 10.1038/ajg.2017.486. No abstract available.

PMID:
29535442
7.

Miniaturization of the Clonogenic Assay Using Confluence Measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Pichler M, Ritter M, Jakab M, Neureiter D, Kiesslich T.

Int J Mol Sci. 2018 Mar 3;19(3). pii: E724. doi: 10.3390/ijms19030724.

8.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt T, Magnes T, Hufnagl C, Thorner AR, Ducar M, Neureiter D, Tränkenschuh W, Klieser E, Gaggl A, Rösch S, Rasp G, Hartmann TN, Pleyer L, Rinnerthaler G, Weiss L, Greil R, Egle A.

Eur J Cancer. 2018 Apr;93:69-78. doi: 10.1016/j.ejca.2018.01.064. Epub 2018 Mar 20.

PMID:
29477794
9.

Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model.

Primavesi F, Swierczynski S, Klieser E, Kiesslich T, Jäger T, Urbas R, Hutter J, Neureiter D, Öfner D, Stättner S.

Oncol Lett. 2018 Mar;15(3):2913-2920. doi: 10.3892/ol.2017.7634. Epub 2017 Dec 18.

10.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer F, Weiss L, Faber V, Neureiter D, Egle A, Geissler K, Voskova D, Zebisch A, Burgstaller S, Pichler A, Stauder R, Sperr W, Lang A, Pfeilstöcker M, Machherndl-Spandl S, Stampfl M, Greil R, Pleyer L.

Wien Klin Wochenschr. 2018 Feb;130(3-4):115-125. doi: 10.1007/s00508-018-1315-2. Epub 2018 Jan 30.

11.

Cartilage Morphological and Histological Findings After Reconstruction of the Glenoid With an Iliac Crest Bone Graft.

Auffarth A, Resch H, Matis N, Hudelmaier M, Wirth W, Forstner R, Neureiter D, Traweger A, Moroder P.

Am J Sports Med. 2018 Apr;46(5):1039-1045. doi: 10.1177/0363546517749813. Epub 2018 Jan 19.

PMID:
29350537
12.

Single-center implementation of endoscopic submucosal dissection (ESD) in the colorectum: Low recurrence rate after intention-to-treat ESD.

Wagner A, Neureiter D, Kiesslich T, Wolkersdörfer GW, Pleininger T, Mayr C, Dienhart C, Yahagi N, Oyama T, Berr F.

Dig Endosc. 2018 May;30(3):354-363. doi: 10.1111/den.12995. Epub 2018 Jan 3.

PMID:
29218732
13.

Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer.

Neureiter D, Kiesslich T, Ritter M, Mayr C.

Expert Opin Ther Targets. 2018 Jan;22(1):1-3. doi: 10.1080/14728222.2018.1406923. Epub 2017 Nov 20. No abstract available.

PMID:
29148857
14.

The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.

Mayr C, Helm K, Jakab M, Ritter M, Shrestha R, Makaju R, Wagner A, Pichler M, Beyreis M, Staettner S, Jaeger T, Klieser E, Kiesslich T, Neureiter D.

Hum Pathol. 2018 Feb;72:117-126. doi: 10.1016/j.humpath.2017.11.003. Epub 2017 Nov 11.

PMID:
29133140
15.

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.

Gruber W, Peer E, Elmer DP, Sternberg C, Tesanovic S, Del Burgo P, Coni S, Canettieri G, Neureiter D, Bartz R, Kohlhof H, Vitt D, Aberger F.

Int J Cancer. 2018 Mar 1;142(5):968-975. doi: 10.1002/ijc.31117. Epub 2017 Nov 6.

16.

Hailey-Hailey Disease and Reduction Mammoplasty: Surgical Treatment of a Gene Mutation.

Schwaiger K, Neureiter J, Neureiter D, Hladik M, Wechselberger G.

Aesthetic Plast Surg. 2018 Feb;42(1):331-332. doi: 10.1007/s00266-017-0963-3. Epub 2017 Sep 15. No abstract available.

PMID:
28916958
17.

Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers-reply.

Neureiter D, Kiesslich T.

Hum Pathol. 2018 Jan;71:167-168. doi: 10.1016/j.humpath.2017.07.016. Epub 2017 Sep 2. No abstract available.

PMID:
28873357
18.

Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis.

Feichtinger RG, Neureiter D, Skaria T, Wessler S, Cover TL, Mayr JA, Zimmermann FA, Posselt G, Sperl W, Kofler B.

Oxid Med Cell Longev. 2017;2017:1320241. doi: 10.1155/2017/1320241. Epub 2017 Jun 28.

19.

The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle A.

Pharmacogenomics J. 2018 May 22;18(3):474-479. doi: 10.1038/tpj.2017.37. Epub 2017 Jul 18.

PMID:
28719596
20.

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.

Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, Gampenrieder S, Moser G, Gaggl A, Greil R, Egle A.

PLoS One. 2017 Jul 7;12(7):e0180995. doi: 10.1371/journal.pone.0180995. eCollection 2017.

21.

Applicability of American Joint Committee on Cancer and College of American Pathologists Regression Grading System in Rectal Cancer.

Jäger T, Neureiter D, Urbas R, Klieser E, Hitzl W, Emmanuel K, Dinnewitzer A.

Dis Colon Rectum. 2017 Aug;60(8):815-826. doi: 10.1097/DCR.0000000000000806.

PMID:
28682967
22.

Biliary tract cancer stem cells - translational options and challenges.

Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T.

World J Gastroenterol. 2017 Apr 14;23(14):2470-2482. doi: 10.3748/wjg.v23.i14.2470. Review.

23.

Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.

Klieser E, Urbas R, Stättner S, Primavesi F, Jäger T, Dinnewitzer A, Mayr C, Kiesslich T, Holzmann K, Di Fazio P, Neureiter D, Swierczynski S.

Hum Pathol. 2017 Jul;65:41-52. doi: 10.1016/j.humpath.2017.02.009. Epub 2017 Feb 22.

PMID:
28235630
24.

Vascular inflammation and media calcification are already present in early stages of chronic kidney disease.

Benz K, Varga I, Neureiter D, Campean V, Daniel C, Heim C, Reimann A, Weyand M, Hilgers KF, Amann K.

Cardiovasc Pathol. 2017 Mar - Apr;27:57-67. doi: 10.1016/j.carpath.2017.01.004. Epub 2017 Jan 23.

PMID:
28171827
25.

T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Catakovic K, Klieser E, Neureiter D, Geisberger R.

Cell Commun Signal. 2017 Jan 5;15(1):1. doi: 10.1186/s12964-016-0160-z. Review.

26.

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D.

Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27. No abstract available.

PMID:
28004600
27.

Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers.

Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T.

Biomed Res Int. 2016;2016:4805270. Epub 2016 Nov 9. Review.

28.

Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.

Urbas R, Mayr C, Klieser E, Fuereder J, Bach D, Stättner S, Primavesi F, Jaeger T, Stanzer S, Ress AL, Löffelberger M, Wagner A, Berr F, Ritter M, Pichler M, Neureiter D, Kiesslich T.

Int J Mol Sci. 2016 Dec 7;17(12). pii: E2053.

29.

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):289-296. doi: 10.1097/MEG.0000000000000789.

PMID:
27906753
30.

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L.

Wien Klin Wochenschr. 2017 Feb;129(3-4):141-144. doi: 10.1007/s00508-016-1124-4.

31.

Trigger Finger Caused by Extraskeletal Chondroma.

Schwaiger K, Ensat F, Neureiter D, Wechselberger G, Hladik M.

J Hand Surg Am. 2017 Jan;42(1):e51-e55. doi: 10.1016/j.jhsa.2016.10.003. Epub 2016 Nov 3.

PMID:
27817941
32.

NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, Weiss L, Gary T, Neureiter D, Klieser E, Greil R, Neumeister P, Egle A, Pichler M.

Br J Cancer. 2016 Nov 8;115(10):1264-1272. doi: 10.1038/bjc.2016.325. Epub 2016 Oct 20.

33.

Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid.

Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

J Clin Gastroenterol. 2017 Mar;51(3):268-277. doi: 10.1097/MCG.0000000000000581.

PMID:
27380461
34.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle A.

Oncotarget. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860.

35.

Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review.

Klieser E, Swierczynski S, Mayr C, Jäger T, Schmidt J, Neureiter D, Kiesslich T, Illig R.

World J Gastrointest Pathophysiol. 2016 May 15;7(2):199-210. doi: 10.4291/wjgp.v7.i2.199. Review.

36.

Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

Klieser E, Pichelstorfer M, Weyland D, Kemmerling R, Swierczynski S, Dinnewitzer A, Jäger T, Kiesslich T, Neureiter D, Illig R.

Mol Clin Oncol. 2016 May;4(5):763-773. Epub 2016 Mar 11.

37.

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.

Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M, Slater EP, Bartsch DK, Illig R, Neureiter D, Wissniowski TT.

Oncotarget. 2016 May 17;7(20):28998-9010. doi: 10.18632/oncotarget.8585.

38.

ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.

Krenn PW, Hofbauer SW, Pucher S, Hutterer E, Hinterseer E, Denk U, Asslaber D, Ganghammer S, Sternberg C, Neureiter D, Aberger F, Wickström SA, Egle A, Greil R, Hartmann TN.

Cancer Res. 2016 Apr 15;76(8):2186-96. doi: 10.1158/0008-5472.CAN-15-3379. Epub 2016 Feb 2.

39.

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer F, Melchardt T, Tränkenschuh W, Neureiter D, Moser G, Magnes T, Weiss L, Schlattau A, Hufnagl C, Ricken G, Höftberger R, Greil R, Egle A.

BMC Cancer. 2015 Dec 22;15:996. doi: 10.1186/s12885-015-2020-4.

40.

Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy.

Klieser E, Swierczynski S, Mayr C, Schmidt J, Neureiter D, Kiesslich T, Illig R.

World J Gastrointest Oncol. 2015 Dec 15;7(12):473-83. doi: 10.4251/wjgo.v7.i12.473. Review.

41.

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, Greil R, Pichler M, Egle A.

J Natl Compr Canc Netw. 2015 Dec;13(12):1501-8.

PMID:
26656519
42.

The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.

Troppan KT, Melchardt T, Wenzl K, Schlick K, Deutsch A, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Tränkenschuh W, Greil R, Neumeister P, Egle A, Pichler M.

J Clin Pathol. 2016 Apr;69(4):326-30. doi: 10.1136/jclinpath-2015-203356. Epub 2015 Dec 7.

PMID:
26644520
43.

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M, Kiesslich T.

Oncotarget. 2016 Jan 5;7(1):745-58. doi: 10.18632/oncotarget.6378.

44.

Deficiency of respiratory chain complex I in Hashimoto thyroiditis.

Zimmermann FA, Neureiter D, Feichtinger RG, Trost A, Sperl W, Kofler B, Mayr JA.

Mitochondrion. 2016 Jan;26:1-6. doi: 10.1016/j.mito.2015.11.002. Epub 2015 Nov 7.

PMID:
26554844
45.

Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.

Klieser E, Illig R, Státtner S, Primavesi F, Jáger T, Swierczynski S, Kiesslich T, Kemmerling R, Bollmann C, Di Fazio P, Neureiter D.

Anticancer Res. 2015 Nov;35(11):6127-36.

PMID:
26504039
46.

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkenschuh W, Greil R, Egle A.

BMC Cancer. 2015 Oct 16;15:725. doi: 10.1186/s12885-015-1776-x.

47.

[Impact of anastomotic leakage on long-term survival in mid-to-low rectal cancer].

Jäger T, Nawara C, Neureiter D, Holzinger J, Öfner-Velano D, Dinnewitzer A.

Chirurg. 2015 Nov;86(11):1072-82. doi: 10.1007/s00104-015-0090-0. German.

PMID:
26428227
48.

Relative Uptake Factor of Invasive Ductal Breast Cancer in Breast-specific Gamma Imaging as a Surrogate Parameter for Sub-typing.

Meissnitzer T, Meissnitzer MW, Seymer A, Hergan K, Neureiter D.

Anticancer Res. 2015 Oct;35(10):5671-7.

PMID:
26408742
49.

3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.

Mayr C, Wagner A, Stoecklinger A, Jakab M, Illig R, Berr F, Pichler M, Di Fazio P, Ocker M, Neureiter D, Kiesslich T.

Anticancer Res. 2015 Sep;35(9):4697-705.

PMID:
26254359
50.

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.

Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2374-81. doi: 10.1158/1535-7163.MCT-15-0121. Epub 2015 Jul 23.

Supplemental Content

Loading ...
Support Center